Recon: J&J buys experimental eczema drug from Numab for $1.25B; Asahi Kasei to acquire Calliditas in $1.1B deal
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States